Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06IBG
|
|||
| Former ID |
DNCL003830
|
|||
| Drug Name |
MK-3415A
|
|||
| Synonyms |
Actoxumab/bezlotoxumab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Clostridium infection [ICD-11: 1A04; ICD-10: A04.7] | Phase 3 | [1] | |
| Malaria [ICD-11: 1F40-1F45] | Phase 3 | [1] | ||
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Clostridium difficile Toxin A (CD toxA) | Target Info | . | [1] |
| Clostridium difficile Toxin B (CD toxB) | Target Info | . | [1] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.